X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
INDRAPRASTHA MEDICAL Fact Sheet, INDRAPRASTHA MEDICAL Financial Results - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

INDRAPRASTHA MEDICAL Fact Sheet   (IRMED)

Here is the latest financial fact sheet of INDRAPRASTHA MEDICAL. For more details, see the INDRAPRASTHA MEDICAL quarterly results and INDRAPRASTHA MEDICAL share price and chart. For a sector overview, read our pharmaceuticals sector report.

INDRAPRASTHA MEDICAL Price History

Price Rs 51.7
Mkt Cap Rs m 4,735
Vol '000 1.4
P/E X 17.0
P/CF X 7.4
EPS (TTM) Rs 3.0
% ch % 0.5
No. of shares m 91.67
% ch week % -0.3
% ch 1-mth % 0.7
% ch 12-mth % -11.6
52 week H/L Rs 64.3/45.0
(As on Oct 24, 2017 11:06:00 AM)
* Results Consolidated
Excel EXPORT | DO YOU LIKE THESE FACTSHEETS? TELL US!

INDRAPRASTHA MEDICAL Financials

No. of Mths
Year Ending
12
Mar-10
12
Mar-11
12
Mar-12
12
Mar-13
12
Mar-14
5-Yr Chart
Click to enlarge
INDRAPRASTHA MEDICAL EQUITY SHARE DATA
High Rs5453444241 
Low Rs2830313229 
Sales per share (Unadj.) Rs46.347.554.964.572.0 
Earnings per share (Unadj.) Rs3.43.42.93.13.9 
Diluted earnings per shareRs3.43.42.93.13.9 
Cash flow per share (Unadj.) Rs5.55.75.36.06.9 
Dividends per share (Unadj.) Rs1.601.601.601.601.80 
Adj. dividends per shareRs1.601.601.601.601.80 
Dividend yield (eoy) %3.93.94.34.35.1 
Book value per share (Unadj.) Rs14.816.317.418.720.4 
Adj. book value per shareRs14.816.317.418.720.4 
Shares outstanding (eoy) m91.6791.6791.6791.6791.67 
Bonus/Rights/Conversions  ----- 
Price / Sales ratio x0.90.90.70.60.5 
Avg P/E ratio x12.112.412.711.99.1 
P/CF ratio (eoy) x7.57.37.06.35.1 
Price / Book Value ratio x2.82.52.22.01.7 
Dividend payout %47.247.754.351.046.6 
Avg Mkt Cap Rs m3,7583,8043,4383,4283,222 
No. of employees `0002.93.02.93.23.1 
Total wages/salary Rs m8249851,1781,2661,418 
Avg. sales/employee Rs Th1,444.11,430.61,739.21,871.02,125.7 
Avg. wages/employee Rs Th280.5323.7407.3400.6456.6 
Avg. net profit/employee Rs Th105.7101.093.491.0114.1 
INDRAPRASTHA MEDICAL INCOME DATA
Net Sales Rs m4,2444,3555,0305,9126,600 
Other income Rs m121269197169186 
Total revenues Rs m4,3654,6245,2266,0826,786 
Gross profit Rs m576434481631733 
Depreciation Rs m193216218259281 
Interest Rs m3944598696 
Profit before tax Rs m466443400455542 
Minority Interest Rs m00000 
Prior Period Items Rs m09000 
Extraordinary Inc (Exp) Rs m00000 
Tax Rs m155145130167187 
Profit after tax Rs m311307270288354 
Gross profit margin %13.610.09.610.711.1 
Effective tax rate %33.332.832.536.834.6 
Net profit margin %7.37.15.44.95.4 
INDRAPRASTHA MEDICAL BALANCE SHEET DATA
Current assets Rs m9079501,1941,3201,473 
Current liabilities Rs m1,3191,2821,7631,9621,920 
Net working cap to sales %-9.7-7.6-11.3-10.9-6.8 
Current ratio x0.70.70.70.70.8 
Inventory Days Days88777 
Debtors Days Days2427243236 
Net fixed assets Rs m2,0952,5982,7583,0032,947 
Share capital Rs m917917917917917 
"Free" reserves Rs m440577676793955 
Net worth Rs m1,3571,4931,5931,7101,871 
Long term debt Rs m44427279297258 
Total assets Rs m3,0023,5814,0204,3814,488 
Interest coverage x13.111.27.86.36.7 
Debt to equity ratio x00.30.20.20.1 
Sales to assets ratio x1.41.21.31.31.5 
Return on assets %11.69.88.28.510.0 
Return on equity %22.920.617.016.818.9 
Return on capital %36.025.824.527.029.9 
Exports to sales %00000 
Imports to sales %2.97.12.84.01.8 
Exports (fob) Rs m00000 
Imports (cif) Rs m122308140238116 
Fx inflow Rs m4015477367031,116 
Fx outflow Rs m141344197319218 
Net fx Rs m260203539384898 
INDRAPRASTHA MEDICAL CASH FLOW
From Operations Rs m 730 334 555 669 581 
From Investments Rs m -361 -573 -280 -540 -218 
From Financial Activity Rs m -357 219 -268 -126 -361 
Net Cashflow Rs m 13 -20 7 3 2 
* Results Consolidated
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Share Holding

Indian Promoters 49.4%
Foreign collaborators 1.6%
Indian inst/Mut Fund 1.3%
FIIs 0.5%
ADR/GDR 0.0%
Free float 47.2%
Shareholders 38,169
Pledged promoter(s) holding 0.0%
 

Company Information

REGD OFF Sarita Vihar, Delhi - Mathura Road, New Delhi - 110 076
E-MAIL asinghal@apollohospitals.com WEB www.apollohospdelhi.com
TELEPHONE (011) 2692 5858 FAX (011) 2682 5601
SECTOR HEALTH SERVICES GROUP MISCELLANEOUS
TR AGENT Link Intime India, 44, 2nd Flr., Naraina Indl. Area, Phase I, New Delhi-28
AUDITOR S. C. Vasudeva & Co.
CHM: S. K. Srivastava COMP SEC: A. K. Singhal YEAR OF INC: 1900 BSE CODE: 532150 FV (Rs): 10 DIV YIELD (%): 3.5

More Health Services Company Fact Sheets:   ASTRAZENECA PHARMA  ALEMBIC PHARMA  SUVEN LIFE  DIVIS LABORATORIES  ALEMBIC LTD  

Compare INDRAPRASTHA MEDICAL With:   ASTRAZENECA PHARMA  ALEMBIC PHARMA  SUVEN LIFE  DIVIS LABORATORIES  ALEMBIC LTD  

Compare INDRAPRASTHA MEDICAL With:   MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Opens in Green; ONGC & HUL Top Gainers(09:30 am)

Asian stock markets are higher today as Japanese and Hong Kong shares show gains. The Nikkei 225 is up 0.17% while the Hang Seng is up 0.10%.

Views on news

Suven Lifesciences: Profits Decline due to Higher tax outgo in the quarter (Quarterly Results Update - Detailed)

Sep 22, 2017

Muted growth in CRAMS segment continues to impact topline.

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

More Views on News

Most Popular

This Rs 71 Trillion Business Could Make or Break (Your) Wealth in the Next Decade(The 5 Minute Wrapup)

Oct 17, 2017

How to profit from behavioral biases afflicting the industry.

Electric Vehicles: The Final Piece of the Puzzle(Smart Contrarian)

Oct 16, 2017

Just as there would be gainers from an electric vehicles boom, who possibly could be the biggest losers.

The Delusional Optimism of India's Real Estate Companies(Vivek Kaul's Diary)

Oct 16, 2017

This is a sector which hasn't gone anywhere in nearly six years, but those who run it continue to remain optimistic.

How Many Shares Should One Buy?(Daily Profit Hunter)

Oct 18, 2017

How much to buy is the biggest challenge after deciding what to buy. Here's your solution.

Companies Are Wary of Borrowing(Chart Of The Day)

Oct 17, 2017

How to profit from behavioral biases afflicting the industry.

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2018
Get our special report, Multibagger Stocks Guide (2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

TRACK INDRAPRASTHA MEDICAL

  • Track your investment in INDRAPRASTHA MEDICAL with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON INDRAPRASTHA MEDICAL

INDRAPRASTHA MEDICAL 8-QTR ANALYSIS

COMPARE INDRAPRASTHA MEDICAL WITH

MARKET STATS